A recent study demonstrated that a tumor inflammation signature incorporating 18 genes that measure adaptive immune response within tumors is correlated with clinical sensitivity to PD-1/PD-L1 immunotherapy [295]. The gene discussed is PDCD1; the disease is neoplasm.